Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies.

Dudley DT, Li XY, Hu CY, Kleer CG, Willis AL, Weiss SJ.

Proc Natl Acad Sci U S A. 2014 Oct 14;111(41):14882-7. doi: 10.1073/pnas.1410996111. Epub 2014 Sep 29.

2.

Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.

Kinsey SG, Naidu PS, Cravatt BF, Dudley DT, Lichtman AH.

Pharmacol Biochem Behav. 2011 Oct;99(4):718-25. doi: 10.1016/j.pbb.2011.06.022. Epub 2011 Jun 29.

3.

Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor.

Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, Beidler D, Liimatta MB, Smith SE, Dudley DT, Sadagopan N, Bhattachar SN, Kesten SJ, Nomanbhoy TK, Cravatt BF, Ahn K.

ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.

4.

Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain.

Ahn K, Smith SE, Liimatta MB, Beidler D, Sadagopan N, Dudley DT, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, Nomura DK, Bhattachar SN, Stiff C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF.

J Pharmacol Exp Ther. 2011 Jul;338(1):114-24. doi: 10.1124/jpet.111.180257. Epub 2011 Apr 19.

5.

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

Barrett SD, Bridges AJ, Dudley DT, Saltiel AR, Fergus JH, Flamme CM, Delaney AM, Kaufman M, LePage S, Leopold WR, Przybranowski SA, Sebolt-Leopold J, Van Becelaere K, Doherty AM, Kennedy RM, Marston D, Howard WA Jr, Smith Y, Warmus JS, Tecle H.

Bioorg Med Chem Lett. 2008 Dec 15;18(24):6501-4. doi: 10.1016/j.bmcl.2008.10.054. Epub 2008 Oct 15.

PMID:
18952427
6.

Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms.

Thiel MJ, Schaefer CJ, Lesch ME, Mobley JL, Dudley DT, Tecle H, Barrett SD, Schrier DJ, Flory CM.

Arthritis Rheum. 2007 Oct;56(10):3347-57.

7.

Design and synthesis of phenethyl benzo[1,4]oxazine-3-ones as potent inhibitors of PI3Kinasegamma.

Lanni TB Jr, Greene KL, Kolz CN, Para KS, Visnick M, Mobley JL, Dudley DT, Baginski TJ, Liimatta MB.

Bioorg Med Chem Lett. 2007 Feb 1;17(3):756-60. Epub 2006 Oct 28.

PMID:
17095227
8.

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

Ohren JF, Chen H, Pavlovsky A, Whitehead C, Zhang E, Kuffa P, Yan C, McConnell P, Spessard C, Banotai C, Mueller WT, Delaney A, Omer C, Sebolt-Leopold J, Dudley DT, Leung IK, Flamme C, Warmus J, Kaufman M, Barrett S, Tecle H, Hasemann CA.

Nat Struct Mol Biol. 2004 Dec;11(12):1192-7. Epub 2004 Nov 14. Erratum in: Nat Struct Mol Biol. 2005 Mar;12(3):278.

PMID:
15543157
9.

Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.

Delaney AM, Printen JA, Chen H, Fauman EB, Dudley DT.

Mol Cell Biol. 2002 Nov;22(21):7593-602.

11.

Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo.

Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR.

Nat Med. 1999 Jul;5(7):810-6.

PMID:
10395327
12.

PD98059 is an equipotent antagonist of the aryl hydrocarbon receptor and inhibitor of mitogen-activated protein kinase kinase.

Reiners JJ Jr, Lee JY, Clift RE, Dudley DT, Myrand SP.

Mol Pharmacol. 1998 Mar;53(3):438-45.

PMID:
9495809
13.

The role of arachidonic acid in the secretion of the amyloid precursor protein (APP).

Emmerling MR, Dudley DT, Dyer RD, Carroll RT, Doyle PD, Davis RE.

Ann N Y Acad Sci. 1996 Jan 17;777:310-5.

PMID:
8624105
14.
15.

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.

Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR.

J Biol Chem. 1995 Nov 17;270(46):27489-94.

16.

A synthetic inhibitor of the mitogen-activated protein kinase cascade.

Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR.

Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9.

17.

Modulation of angiotensin II receptor (AT2) mRNA levels in R3T3 cells.

Camp HS, Dudley DT.

Receptor. 1995 Summer;5(2):123-32.

PMID:
7580938
18.
19.

Structure-activity relationships of C-terminal endothelin hexapeptide antagonists.

Doherty AM, Cody WL, DePue PL, He JX, Waite LA, Leonard DM, Leitz NL, Dudley DT, Rapundalo ST, Hingorani GP, et al.

J Med Chem. 1993 Sep 3;36(18):2585-94.

PMID:
8410970
20.

Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells.

Dudley DT, Summerfelt RM.

Regul Pept. 1993 Mar 19;44(2):199-206.

PMID:
8469774
21.

Subtype selective muscarinic agonists: potential therapeutic agents for Alzheimer's disease.

Davis R, Raby C, Callahan MJ, Lipinski W, Schwarz R, Dudley DT, Lauffer D, Reece P, Jaen J, Tecle H.

Prog Brain Res. 1993;98:439-45. Review. No abstract available.

PMID:
8248534
22.

Design of a functional hexapeptide antagonist of endothelin.

Cody WL, Doherty AM, He JX, DePue PL, Rapundalo ST, Hingorani GA, Major TC, Panek RL, Dudley DT, Haleen SJ, et al.

J Med Chem. 1992 Aug 21;35(17):3301-3. No abstract available. Erratum in: J Med Chem 1993 Jan 22;36(2):304.

PMID:
1324321
23.

Characterization of angiotensin II (AT2) binding sites in R3T3 cells.

Dudley DT, Hubbell SE, Summerfelt RM.

Mol Pharmacol. 1991 Sep;40(3):360-7.

PMID:
1896025
24.

Amylin increases cyclic AMP formation in L6 myocytes through calcitonin gene-related peptide receptors.

Zhu GC, Dudley DT, Saltiel AR.

Biochem Biophys Res Commun. 1991 Jun 14;177(2):771-6.

25.

Subclasses of angiotensin II binding sites and their functional significance.

Dudley DT, Panek RL, Major TC, Lu GH, Bruns RF, Klinkefus BA, Hodges JC, Weishaar RE.

Mol Pharmacol. 1990 Sep;38(3):370-7.

PMID:
2402226
26.

The phosphatidylinositol response of chondrocytes in culture.

Baragi VM, Dudley DT, Schrier DJ.

Agents Actions. 1989 Jun;27(3-4):428-30.

PMID:
2508445
27.

Functional differences in insulin receptors in rat adipocyte and human placenta membranes.

Swanson ML, Dudley DT, Walker PS, Boyle TR, Pessin JE.

Endocrinology. 1988 Mar;122(3):967-75.

PMID:
3277840
28.
29.

Phospholipid activation of the insulin receptor kinase: regulation by phosphatidylinositol.

Sweet LJ, Dudley DT, Pessin JE, Spector AA.

FASEB J. 1987 Jul;1(1):55-9.

PMID:
3038645
30.
31.

Inositol phospholipid arachidonic acid metabolism in GH3 pituitary cells.

Dudley DT, Spector AA.

Biochem J. 1986 May 15;236(1):235-42.

32.
33.

Comparative utilization of n-3 polyunsaturated fatty acids by cultured human Y-79 retinoblastoma cells.

Yorek MA, Bohnker RR, Dudley DT, Spector AA.

Biochim Biophys Acta. 1984 Sep 12;795(2):277-85.

PMID:
6089899
34.
35.

Fatty acid alteration of L1210 murine leukemia cells. Growth rate and stability of lipid changes in culture.

Burns CP, Luttenegger DG, Dudley DT.

J Natl Cancer Inst. 1980 Nov;65(5):987-91. No abstract available.

PMID:
6933265
36.
37.

Effect of modification of plasma membrane fatty acid composition on fluidity and methotrexate transport in L1210 murine leukemia cells.

Burns CP, Luttenegger DG, Dudley DT, Buettner GR, Spector AA.

Cancer Res. 1979 May;39(5):1726-32. No abstract available.

Supplemental Content

Loading ...
Support Center